Aside from ibrutinib, patients with M-CLL, devoid of TP53 aberrations and fit plenty of to tolerate FCR therapy, may still be superior candidates with the latter, While using the advantage remaining that this remedy is usually finished in six months when ibrutinib needs to be taken indefinitely. This feature can be specially important for non-compl